REBIRTH Mitglieder

Sauer, Martin

Sauer, Martin, Prof. Dr. med.

Klinik für Pädiatrische Hämatologie und Onkologie, Medizinische Hochschule Hannover


Biography / About

Date of Birth:July, 1967
Function:Deputy Chair

Education:

11/1988 – 07/1990Preclinical studies: University of Regensburg, Medical School of Regensburg, Bavaria, Germany
11/1990 – 04/1995M.D., University of Erlangen - Nürnberg, School of Medicine Germany
03/1994 – 12/1994Scholarship of the European Community for a 1 year study at the University of Rennes, School of Medicine, France
10/1996USMLE Step 1, score: 89/225
03/1997USMLE Step 2, score: 84/209, ECFMG – Certificate: indefinite (Nr: 0-563-142-9)

Academic appointments and Research posts:

06/1995 – 06/1999Residency Program in Pediatrics, University of Jena, School of Medicine, Germany. Special priority on pediatric hematology, oncology and bone marrow transplantation.
10/1998 – 06/1999Max-Planck-Group for Experimental Hemostaseology affiliated with the Friedrich-Schiller-University of Jena
07/1999 – 07/2003Clinical Fellowship, Pediatric Hematology/Oncology and Bone Marrow Transplantation, University of Minnesota, USA
10/2003 – 09/2004Instructor, Pediatric Hematology/ Oncology and Bone Marrow Transplantation, Medical School Hannover (MHH)
Since 10/2004Assistant Professor, Pediatric Hematology/ Oncology and Bone Marrow Transplantation, MHH
Since 07/2010Deputy Chair, Pediatric Hematology/ Oncology and Bone Marrow Transplantation, MHH

Other professional activities:

  • German Society of Pediatrics
  • American Association of Hematology
  • American Society of Clinical Oncology
  • German Society of Pediatric Oncology/Hematology (GPOH)
  • European Society for Blood and Marrow Transplantation
  • EBMT working group for Pediatric BMT

Major research interests:

  • Experimental transplantation for AML
  • TCR-Gen transfer
  • Development of innovative preparative regimens for pediatric BMT
  • Development of MRI-based contrast agents for cellular therapies

Selected Publications:

  1. Rossig C, Pule M, Altvater B, Saiagh S, Wright G, Ghorashian S, Clifton-Hadley L, Champion K, Sattar Z, Popova B, Hackshaw A, Smith P, Roberts T, Biagi E, Dreno B, Rousseau R, Kailayangiri S, Ahlmann M, Hough R, Kremens B, Sauer MG, Veys P, Goulden N, Cummins M, Amrolia PJ. Vaccination to improve the persistence of CD19CAR gene-modified T cells in relapsed pediatric acute lymphoblastic leukemia. Leukemia. 2017 Jan 27. doi: 10.1038/leu.2017.39. [Epub ahead of print]
  2. Sauer MG, Herbst J, Dieckmann U, Rudd CE, Kardinal C. SHP-1 acts as a key regulator of alloresponses by modulating LFA-1-mediated adhesion in primary murine T cells. Mol Cell Biol. 2016 Nov 28;36(24):3113-3127.
  3. Hübner J, Hoseini SS, Suerth JD, Hoffmann D, Maluski M, Herbst J, Maul H, Ghosh A, Eiz-Vesper B, Yuan Q, Ott M, Heuser M, Schambach A, Sauer MG. Generation of genetically engineered precursor T cells from human umbilical cord blood using an optimized alpharetroviral vector platform. Mol Ther. 2016 Aug;24(7):1216-26
  4. Hoseini SS, Hapke M, Herbst J, Wedekind D, Baumann R, Krueger A, Heinz N, Schiedlmeier B, Vignali D, van den Brink MRM, Schambach A, Blazar BR, Sauer MG. Inducible T-cell receptor expression in precursor T-cells for leukemia control. Leukemia 2015 Jul;29(7):1530-1542
  5. Ghosh A, Dogan Y, Moroz M, Holland A, Yim N, Rao U, Young L, Tannenbaum D, Masih D, Velardi E, Tsai J, Jenq R, Penack O, Hanash A, Smith O, Piersanti K, Lezcano C, Murphy G, Liu C, Palomba ML, Sauer MG, Sadelain M, Ponomarev V, van den Brink M. Fratricidal TRAIL+T cells eliminate alloactivated T cells and augment anti-tumor activity after bone marrow transplantation. JCI 2013 Jun 3;123(6):2654-62
  6. Kempf T, Zarbock A, Widera C, Butz S, Stadtmann A, Rossaint J, Bolomini-Vittori M, Korf-Klingebiel M, Napp LC, Hansen B, Kanwischer A, Bavendiek U, Beutel G, Hapke M, Sauer MG, Laudanna C, Hogg N, Vestweber D, Wollert KC. GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat Med. 2011 May;17(5):581-8.
  7. Koestner W, Hapke M, J Herbst, Klein C, Welte K, Frueauf J, Flatley A, Vignali D, Blazar BR, Sauer MG. PD-L1 blockade effectively restores strong graft-versus-leukemia effects without graft-versus-host-disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD8+ T cells. Blood. 2011 Jan 20;117(3):1030-41.
  8. Ghosh A, Koestner W, Hapke M, Länger F, Baumann R, Könecke C, Welte K, Blazar BR, Sauer MG. In vitro priming of donor T cells on host-derived antigen presenting cells can mediate strong graft versus leukemia effects without graft versus host disease after MHC disparate bone marrow transplantation. Blood. 2009 Apr 30;113(18):4440-8.
  9. Ghosh A, Wolenski M, Klein C, Welte K, Blazar BR, and Sauer MG. Cytotoxic T cells reactive to an immunodominant leukemia-associated antigen can be specifically primed and expanded by combining a specific priming step with non specific large- scale expansion. J Immunother. 2008 Feb-Mar;31(2):121-31.
  10. Sauer MG, Ericson M, Weigel B, Herron M, Angela Panoskaltisis-Mortari, Kren B, Levine B, Serody J, June C, Taylor P, Blazar B. A novel system for simultaneous tracking and biological assessment of leukaemia cells and leukaemia-reactive cytotoxic T-cells (CTLs). Cancer Res 64(11):3914-212 (2004)


[zurück zur Liste]
test
Diese Webseite verwendet Cookies und die Webanalyse-Software Google Analytics. Klicken Sie hier für weitere Informationen zum Datenschutz.
Einverstanden